AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Industry News (Blood Transfusion)
Vitex Files To Commence Trials of New "Universal" Plasma
August 23rd, 1999
V.I. Technologies, Inc., Melville, New York, announced that the company has filed an Investigational New Drug (IND) amendment with the U.S. Food and Drug Administration (FDA) to commence trials of a new version of PLAS+SD which removes the antibodies that cause plasma to be blood-type specific. PLAS+SD is a transfusion plasma product that uses Vitex's solvent detergent process to remove lipid enveloped viruses including HIV, hepatitis C, and hepatitis B. Today, all plasma must be typed before it is administered to a patient. The next generation PLAS+SD removes blood-type specific antibodies (isoagglutinins), making it possible to use this product as...
Source: AIDS Weekly (1999-08-23)
|
